HMG-CoA Reductase: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (11 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
|DATE=December 23, 2010 | |DATE=December 23, 2010 | ||
|OLDID=1159684 | |OLDID=1159684 | ||
|BAMBEDDOI=10.1002/bmb.20481 | |||
}} | }} | ||
<StructureSection load=' | <StructureSection load='' size='350' side='right' scene='HMG-CoA_Reductase/1dq8_starting_scene/1' caption='Crystal Structure of HMG-CoA, (PDB code [[1dq8]])'> | ||
==Function== | ==Function== | ||
[[HMG-CoA Reductase]] (or '''3-hydroxy-3-methyl-glutaryl-CoA reductase''' or '''HMGR''') is the rate-controlling enzyme of the mevalonate pathway, responsible for cholesterol and other isoprenoid biosynthesis. HMGR is a transmembrane protein, containing 8 domains, that is anchored in the membrane of the endoplasmic reticulum.<ref name="Roitelman">PMID:1374417</ref> It is the major target of the Statins | [[HMG-CoA Reductase]] (or '''3-hydroxy-3-methyl-glutaryl-CoA reductase''' or '''HMGR''') is the rate-controlling enzyme of the mevalonate pathway, responsible for cholesterol and other isoprenoid biosynthesis. HMGR is a transmembrane protein, containing 8 domains, that is anchored in the membrane of the endoplasmic reticulum.<ref name="Roitelman">PMID:1374417</ref> It is the major target of the '''Statins''' the best selling pharmaceutical drugs in the world and [[Vytorin]] - cholesterol lowering drug class . See also | ||
[[Ephrin Type-A Receptor]]<br /> | |||
[[Neurodevelopmental Disorders]]<br /> | |||
[[Mevalonate pathway]]<br /> | |||
[[Biosynthesis of cholesterol]]. | |||
[[Image: HMG-CoA_reductase_pathway.png|350px|left|thumb| Mevalonate Pathway. Note the early stage at which the statins interfere in the pathway]] | [[Image: HMG-CoA_reductase_pathway.png|350px|left|thumb| Mevalonate Pathway. Note the early stage at which the statins interfere in the pathway]] | ||
{{clear}} | {{clear}} | ||
| Line 42: | Line 47: | ||
==Medical Implications== | ==Medical Implications== | ||
[[Image: HMGCoA to Lovastatin Comparison.jpg|200px|left|thumb| Comparison of Chemical Structure of HMG-CoA and Lovastatin]] | [[Image: HMGCoA to Lovastatin Comparison.jpg|200px|left|thumb| Comparison of Chemical Structure of HMG-CoA and Lovastatin]] | ||
{{Clear}} | {{Clear}} | ||
| Line 53: | Line 57: | ||
See<br /> | See<br /> | ||
[[Statin Pharmacokinetics]]<br /> | [[Statin Pharmacokinetics]]<br /> | ||
[[Lovastatin-Mevacor]]<br /> | |||
[[Treatments:Hypercholeseterolemia]]<br /> | [[Treatments:Hypercholeseterolemia]]<br /> | ||
[[Treatments:Statin Pharmacokinetics References]]<br />. | [[Treatments:Statin Pharmacokinetics References]]<br />. | ||
<br /> | <br /> | ||
==3D Structures of HMG-CoA Reductase== | ==3D Structures of HMG-CoA Reductase== | ||
[[HMG-CoA Reductase 3D structures]] | |||
</StructureSection> | |||
==Additional Resources== | ==Additional Resources== | ||
